Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC

Patients with non-small cell lung cancer (NSCLC) that harbors epidermal growth factor receptor (EGFR) mutations initially respond to EGFR-tyrosine kinase inhibitors (TKI) but eventually experience relapse. Acquired resistance to EGFR-TKIs is strongly associated with patient mortality. Thus, elucidat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer research 2013-07, Vol.11 (7), p.759-767
Hauptverfasser:	Terai, Hideki, Soejima, Kenzo, Yasuda, Hiroyuki, Nakayama, Sohei, Hamamoto, Junko, Arai, Daisuke, Ishioka, Kota, Ohgino, Keiko, Ikemura, Shinnosuke, Sato, Takashi, Yoda, Satoshi, Satomi, Ryosuke, Naoki, Katsuhiko, Betsuyaku, Tomoko
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis - drug effects Autocrine Communication - drug effects Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - pathology Cell Line, Tumor Clone Cells Drug Resistance, Neoplasm - drug effects Drug Synergism Fibroblast Growth Factor 2 - antagonists & inhibitors Fibroblast Growth Factor 2 - metabolism Humans Lung Neoplasms Models, Biological Pyrimidines - pharmacology Quinazolines - pharmacology Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors Receptor, Fibroblast Growth Factor, Type 1 - metabolism RNA, Small Interfering - metabolism Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!